1		AN ACT relating to agriculture.
2	Be i	t enacted by the General Assembly of the Commonwealth of Kentucky:
3		→ SECTION 1. KRS 260.850 IS REPEALED AND REENACTED TO READ AS
4	FOL	LOWS:
5	<u>As u</u>	used in Sections 1 to 13 of this Act:
6	<u>(1)</u>	"Commissioner" means the Commissioner of the Kentucky Department of
7		Agriculture;
8	<u>(2)</u>	"Cultivating" means planting, growing, and harvesting a plant or crop;
9	<u>(3)</u>	"Department" means the Kentucky Department of Agriculture;
10	<u>(4)</u>	"Handling" means possessing or storing industrial hemp for any period of time
11		on premises owned, operated, or controlled by a person licensed to cultivate or
12		process industrial hemp. "Handling" also includes possessing or storing
13		industrial hemp in a vehicle for any period of time other than or during its actual
14		transport from the premise of a licensed person to cultivate or process industrial
15		hemp to the premise of another licensed person;
16	<u>(5)</u>	"Industrial hemp" has the same meaning as in 7 U.S.C. sec. 5940 as it currently
17		exists or as it may be subsequently amended;
18	<u>(6)</u>	"Industrial hemp products" means products derived from, or made by,
19		processing industrial hemp plants or plant parts;
20	<u>(7)</u>	"Licensee" means an individual or business entity possessing a license issued by
21		the department under the authority of this chapter to grow, handle, cultivate,
22		process, or market industrial hemp or industrial hemp products;
23	<u>(8)</u>	"Marketing" means promoting or selling a product within the Commonwealth,
24		in another state, or outside of the United States. "Marketing" includes efforts to
25		advertise and gather information about the needs or preferences of potential
26		consumers or suppliers;
27	<u>(9)</u>	"Processing" means converting an agricultural commodity into a marketable

Page 1 of 25 SB021840.100 - 1324 - XXXX Senate Committee Substitute

1	<u>form;</u>
2	(10) ''Research pilot program'' means a pilot program conducted by the department in
3	collaboration with one (1) or more licensee or university to study methods of
4	cultivating, processing, or marketing industrial hemp under the authority of 7
5	U.S.C. sec. 5940 as it currently exists or as it may be subsequently amended; and
6	(11) "University" means an accredited institution of higher education located in the
7	Commonwealth.
8	→SECTION 2. A NEW SECTION OF KRS 260.850 to 260.869 IS CREATED
9	TO READ AS FOLLOWS:
10	It is the declared policy of the Commonwealth that industrial hemp is a viable
11	agricultural crop in the Commonwealth. The purposes of Sections 1 to 13 of this Act
12	are to:
13	(1) Promote the research and study methods of cultivating, processing, and
14	marketing industrial hemp;
15	(2) Promote the expansion of the Commonwealth's industrial hemp industry to the
16	maximum extent permitted by federal law, in anticipation of a change in federal
17	law allowing citizens of the Commonwealth to cultivate, handle, or process
18	industrial hemp and industrial hemp products for commercial purposes without
19	participating in research pilot programs; and
20	(3) Move the Commonwealth and its citizens to the forefront of the industrial hemp
21	industry.
22	→SECTION 3. A NEW SECTION OF KRS 260.850 to 260.869 IS CREATED
23	TO READ AS FOLLOWS:
24	(1) The purpose of the research pilot program authorized by this chapter is to enable
25	the department, and its licensees and affiliated universities, to study methods of
26	cultivating, processing, or marketing industrial hemp.
27	(2) Notwithstanding any other provision of law to the contrary, it is lawful for a

Page 2 of 25
SB021840.100 - 1324 - XXXX
Senate Committee Substitute

1		licensee, or his or her agent, to cultivate, handle, or process industrial hemp or
2		industrial hemp products in the Commonwealth.
3	<u>(3)</u>	It is unlawful for a person who does not hold a license issued by the department,
4		or who is not an agent of a licensee, to cultivate, handle, process, or market living
5		industrial hemp plants or viable seeds, leaf materials, or floral materials derived
6		from industrial hemp. Penalties for persons who cultivate, handle, process, or
7		market living industrial hemp plants or viable seeds, leaf materials, or floral
8		materials derived from industrial hemp without a license are the same as those
9		penalties that are applicable to persons who violate KRS Chapter 218A, relating
10		to marijuana.
11	<u>(4)</u>	Nothing in this chapter authorizes any person to violate any federal or state law
12		or regulation.
13		→SECTION 4. A NEW SECTION OF KRS 260.850 to 260.859 IS CREATED
14	TO	READ AS FOLLOWS:
15	<u>(1)</u>	In addition to any other powers vested in it by law, the department shall have the
16		authority and power to promulgate administrative regulations to:
17		(a) Prescribe rules for any industrial hemp pilot program;
18		(b) Conduct one (1) or more industrial hemp research pilot programs;
19		(c) License persons who wish to participate in an industrial hemp research
20		pilot program by cultivating, handling, processing, or marketing industrial
21		<u>hemp;</u>
22		(d) Prescribe rules for a university's participation in, or affiliation with, any
23		industrial hemp research pilot program;
24		(e) Prescribe sampling and testing procedures to ensure that industrial hemp
25		and industrial hemp products cultivated, handled, processed, or marketed
26		under the authority of this section do not exceed the concentration levels
27		defined in 7 U.S.C. sec. 5940 as it currently exists or as it may be

Page 3 of 25
SB021840.100 - 1324 - XXXX
Senate Committee Substitute

1		subsequently amended;
2	<u>(f)</u>	Define classes or categories of industrial hemp products that are eligible for
3		sale, transfer, or distribution to members of the public; and
4	<u>(g)</u>	Establish a schedule of nonrefundable fees for administering any industrial
5		hemp research pilot program.
6	(2) (a)	No person shall cultivate, handle, process, or market industrial hemp in the
7		Commonwealth unless the person holds an industrial hemp license issued
8		by the department.
9	<u>(b)</u>	Any person seeking to cultivate industrial hemp shall provide to the
10		department the legal description and global positioning coordinates
11		sufficient for locating the fields or greenhouses to be used to grow
12		industrial hemp.
13	<u>(c)</u>	Any person seeking to cultivate or process industrial hemp shall provide to
14		the department prior written consent allowing representatives of the
15		department, the Department of Kentucky State Police, and other state and
16		local law enforcement agencies to enter onto all premises where industrial
17		hemp is cultivated, processed, or stored for the purpose of conducting
18		physical inspections or ensuring compliance with the requirements of
19		Sections 1 to 13 of this Act and administrative regulations promulgated by
20		the department.
21	<u>(d)</u>	An applicant for a license issued by the department shall submit to and pay
22		for an annual criminal background check conducted by the Department of
23		Kentucky State Police or another state or federal law enforcement agency
24		selected by the department.
25	<u>(e)</u>	No person who has been convicted of any felony or any drug-related
26		misdemeanor or violation in the previous ten (10) years from the date of
27		application shall be eligible to obtain a license.

Page 4 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

1		→SECTION 5. A NEW SECTION OF KRS 260.850 to 260.859 IS CREATED
2	TO	READ AS FOLLOWS:
3	<u>(1)</u>	The Industrial Hemp Advisory Board is created for the purpose of providing
4		advice and expertise as may be needed by a university or the department with
5		respect to plans, policies, and procedures applicable to the administration of its
6		respective industrial hemp research pilot programs.
7	<u>(2)</u>	The Industrial Hemp Advisory Board shall be attached to the department for
8		administrative purposes.
9	<u>(3)</u>	The Industrial Hemp Advisory Board shall be composed of the following
10		members:
11		(a) The Commissioner of the department or the Commissioner's designee;
12		(b) The executive director of the Governor's Office of Agricultural Policy or the
13		executive director's designee;
14		(c) The dean of the University of Kentucky's College of Agriculture, Food and
15		Environment or the dean's designee;
16		(d) The commissioner of the Department of Kentucky State Police or the
17		<u>commissioner's designee;</u>
18		(e) The president of the Kentucky Sheriff's Association or the president's
19		designee;
20		(f) The president of the Kentucky Association of Chiefs of Police or the
21		president's designee; and
22		(g) Ten (10) at-large members designated by the Commissioner.
23	<u>(4)</u>	The Commissioner or the Commissioner's designee shall serve as chair.
24	<u>(5)</u>	A majority of the members of the board shall constitute a quorum.
25	<u>(6)</u>	The board shall meet at least one (1) time annually at the call of the chair.
26	<u>(7)</u>	In making the initial appointments of the board, the Commissioner shall stagger
2.7		the terms of the hoard members. Thereafter, members shall be appointed to a

Page 5 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

1		term of four (4) years and shall serve until their successors are duly appointed						
2		and qualified.						
3	<u>(8)</u>	Board members shall receive no compensation but shall be reimbursed, payable						
4		from the industrial hemp research pilot program fund, for any actual travel						
5		expense incurred while attending meetings of the board.						
6		Section 6. KRS 260.868 is amended to read as follows:						
7	A po	erson holding a license issued by the department[Industrial hemp growers licensed						
8		under KRS 260.850 to 260.869] may be eligible to receive funds received by the						
9		state under the Master Settlement Agreement and placed in the rural development						
10		fund established in KRS 248.655.						
11		→ Section 7. KRS 260.869 is amended to read as follows:						
12	(1)	There is established in the State Treasury a trust and agency fund entitled the						
13		industrial hemp program fund, to be administered by the commission for the						
14		purpose of covering the costs of the commission and the industrial hemp research						
15		program, as approved by the commission.						
16	(2)	The fund may receive state appropriations, gifts, grants, federal funds, and any other						
17		funds both public and private, and shall receive all license application fees and						
18		license renewal fees collected by the commission. Money deposited in the fund is						
19		hereby appropriated for purposes set out in this section.						
20	(3)	Notwithstanding KRS 45.229, any unallocated or unencumbered balances in the						
21		fund shall be invested as provided in KRS 42.500(9), and any interest or other						
22		income earned from the investments, along with the unallotted or unencumbered						
23		balances in the fund, shall not lapse but shall be carried forward for purposes of the						
24		fund.						
25	<u>(4)</u>	The industrial hemp program fund shall be closed on July 1, 2017. All moneys						
26		remaining in the fund shall be deposited in the industrial hemp research pilot						
27		program fund created under Section 8 of this Act and shall be used for the						

Page 6 of 25
SB021840.100 - 1324 - XXXX
Senate Committee Substitute

1	purposes establishea under that section.
2	→SECTION 8. A NEW SECTION OF KRS 260.850 to 260.859 IS CREATED
3	TO READ AS FOLLOWS:
4	(1) The industrial hemp research pilot program fund is hereby created as a separat
5	trust fund in the State Treasury. The fund shall consist of amounts received from
6	appropriations, and any other proceeds from gifts, grants, federal fund
7	application fees, or license fees provided by Section 4 of this Act, civil penalties a
8	provided by Section 9 of this Act, and any other funds, both public and private
9	made available for purposes of Sections 1 to 13 of this Act.
10	(2) The industrial hemp research pilot program fund shall be administered by the
11	<u>department.</u>
12	(3) Amounts deposited in the industrial hemp research pilot program fund shall b
13	used for the costs of personnel, program administration, testing, actual trave
14	expenses of the advisory board established under Section 6 of this Act, and an
15	other costs incurred while conducting the industrial hemp research pilo
16	programs under Sections 1 to 13 of this Act.
17	(4) Notwithstanding KRS 45.229, the industrial hemp research pilot program fun
18	amounts not expended at the close of a fiscal year shall not lapse but shall b
19	carried forward into the next fiscal year.
20	(5) Any interest earnings of the industrial hemp research pilot program fund sha
21	become part of the fund and shall not lapse.
22	(6) Moneys in the fund are hereby appropriated for the purposes set forth in the
23	section and shall not be appropriated or transferred by the General Assembly for
24	any other purposes unless the industrial hemp research pilot program i
25	discontinued by the Commissioner as provided by Section 10 of this Act. If the
26	program is discontinued, moneys remaining in the fund shall lapse to the
27	General Fund no later than one (1) year after notice of the program

Page 7 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

1		discontinuation, and the fund shall be closed.
2		→SECTION 9. A NEW SECTION OF KRS 260.850 to 260.859 IS CREATED
3	TO	READ AS FOLLOWS:
4	<u>(1)</u>	The department may temporarily suspend a license up to sixty (60) days if the
5		licensee is alleged to have:
6		(a) Violated any provision of Sections 1 to 13 of this Act or an administrative
7		regulation promulgated under the authority of Sections 1 to 13 of this Act;
8		(b) Made any false statement to the department or its representatives;
9		(c) Pled guilty to, or been convicted of, any felony or drug-related misdemeanor
10		or violation;
11		(d) Failed to comply with only those instructions agreed upon in the contract
12		signed by the licensee at the time the industrial hemp license was issued; or
13		(e) Failed to comply with an order from a representative of the department,
14		representative of the Department of Kentucky State Police, or any law
15		enforcement officer.
16	<u>(2)</u>	The department may temporarily suspend a license up to sixty (60) days without
17		giving the licensee advance notice of the charge against him or her or an
18		opportunity to be heard.
19	<u>(3)</u>	The department shall not permanently revoke a license until the department has
20		notified the licensee of the charge against him or her and given the licensee an
21		opportunity for a hearing before a three (3) person panel whose members have
22		been designated by the Commissioner. The three (3) person panel shall include:
23		(a) Two (2) members who are employees of the department; and
24		(b) One (1) member who is not an employee of the department.
25	<u>(4)</u>	The department may permanently revoke a license if the licensee admits, or is
26		found in a hearing, to have:
27		(a) Violated any provision of Sections 1 to 13 of this Act or an administrative

Page 8 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

1	regulation promulgated under the authority of Sections 1 to 13 of this Act;
2	(b) Made any false statement to the department or its representative;
3	(c) Pled guilty to, or been convicted of, any felony or drug-related misdemeanor
4	or violation; or
5	(d) Failed to comply with any instruction or order from the department, a
6	representative of the Department of Kentucky State Police, or any law
7	enforcement officer.
8	(5) The department may impose a monetary civil penalty, not to exceed two thousand
9	five hundred dollars (\$2,500) per violation, on any person who violates Sections 1
10	to 13 of this Act or an administrative regulation promulgated under the authority
11	of Sections 1 to 13 of this Act.
12	(6) The department shall not impose a monetary civil penalty against a person
13	alleged to have violated Sections 1 to 13 of this Act, or an administrative
14	regulation promulgated under the authority of Sections 1 to 13 of this Act, until
15	the department has notified the person of the charge against him or her and
16	given the person the opportunity for a hearing before the three (3) person panel.
17	→SECTION 10. A NEW SECTION OF KRS 260.850 to 260.859 IS CREATED
18	TO READ AS FOLLOWS:
19	(1) Notwithstanding any provision of law to the contrary, the department may
20	discontinue the industrial hemp research pilot program if the Commissioner
21	finds that:
22	(a) A change in federal law makes continuation of the industrial hemp
23	research pilot program impractical or impossible; or
24	(b) A change in federal law allows citizens of the Commonwealth to cultivate,
25	handle, or process industrial hemp and industrial hemp products without
26	participating in a research pilot program conducted by the department.
27	(2) The Commissioner shall notify, in writing, the Governor, the Speaker of the

Page 9 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

1		House of Representatives, and the President of the Senate, that the industrial
2		hemp research pilot program has been discontinued.
3		→ SECTION 11. A NEW SECTION OF KRS CHAPTER 250 IS CREATED TO
4	REA	AD AS FOLLOWS:
5	<u>The</u>	director, or the director's designee, shall receive samples and test industrial hemp
6	<u>plan</u>	ts, plant parts, and materials grown or located within the Commonwealth in order
7	to d	etermine whether the industrial hemp plants, plant parts, and materials are in
8	<u>com</u>	pliance with the provisions of Sections 1 to 13 of this Act and the administrative
9	regu	lations promulgated thereunder.
10		→ Section 12. KRS 218A.010 is amended to read as follows:
11	As u	sed in this chapter:
12	(1)	"Administer" means the direct application of a controlled substance, whether by
13		injection, inhalation, ingestion, or any other means, to the body of a patient or
14		research subject by:
15		(a) A practitioner or by his or her authorized agent under his or her immediate
16		supervision and pursuant to his or her order; or
17		(b) The patient or research subject at the direction and in the presence of the
18		practitioner;
19	(2)	"Anabolic steroid" means any drug or hormonal substance chemically and
20		pharmacologically related to testosterone that promotes muscle growth and includes
21		those substances listed in KRS 218A.090(5) but does not include estrogens,
22		progestins, and anticosteroids;
23	(3)	"Cabinet" means the Cabinet for Health and Family Services;
24	(4)	"Child" means any person under the age of majority as specified in KRS 2.015;

"Controlled substance" means methamphetamine, or a drug, substance, or 27 (6)

and geometric isomers, and salts of isomers;

24

25

26

(5)

SB021840.100 - 1324 - XXXX Senate Committee Substitute

"Cocaine" means a substance containing any quantity of cocaine, its salts, optical

1		imm	nediate	e precursor in Schedules I through V and includes a controlled substance			
2		anal	analogue;				
3	(7)	(a)	"Co	ntrolled substance analogue," except as provided in paragraph (b) of this			
4			subs	section, means a substance:			
5			1.	The chemical structure of which is substantially similar to the structure			
6				of a controlled substance in Schedule I or II; and			
7			2.	Which has a stimulant, depressant, or hallucinogenic effect on the			
8				central nervous system that is substantially similar to or greater than the			
9				stimulant, depressant, or hallucinogenic effect on the central nervous			
10				system of a controlled substance in Schedule I or II; or			
11			3.	With respect to a particular person, which such person represents or			
12				intends to have a stimulant, depressant, or hallucinogenic effect on the			
13				central nervous system that is substantially similar to or greater than the			
14				stimulant, depressant, or hallucinogenic effect on the central nervous			
15				system of a controlled substance in Schedule I or II.			
16		(b)	Such	n term does not include:			
17			1.	Any substance for which there is an approved new drug application;			
18			2.	With respect to a particular person, any substance if an exemption is in			
19				effect for investigational use for that person pursuant to federal law to			
20				the extent conduct with respect to such substance is pursuant to such			
21				exemption; or			
22			3.	Any substance to the extent not intended for human consumption before			
23				the exemption described in subparagraph 2. of this paragraph takes			
24				effect with respect to that substance;			
25	(8)	"Co	unterf	eit substance" means a controlled substance which, or the container or			
26		labe	eling o	of which, without authorization, bears the trademark, trade name, or other			

Page 11 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

27

identifying mark, imprint, number, or device, or any likeness thereof, of a

1		man	ufacturer, distributor, or dispenser other than the person who in fact				
2		man	ufactured, distributed, or dispensed the substance;				
3	(9)	"Dis	pense" means to deliver a controlled substance to an ultimate user or research				
4		subj	ect by or pursuant to the lawful order of a practitioner, including the packaging,				
5		labe	ling, or compounding necessary to prepare the substance for that delivery;				
6	(10)	"Dis	penser" means a person who lawfully dispenses a Schedule II, III, IV, or V				
7		cont	rolled substance to or for the use of an ultimate user;				
8	(11)	"Dis	tribute" means to deliver other than by administering or dispensing a controlled				
9		subs	tance;				
10	(12)	"Dos	sage unit" means a single pill, capsule, ampule, liquid, or other form of				
11		adm	administration available as a single unit;				
12	(13)	"Dru	ng" means:				
13		(a)	Substances recognized as drugs in the official United States Pharmacopoeia,				
14			official Homeopathic Pharmacopoeia of the United States, or official National				
15			Formulary, or any supplement to any of them;				
16		(b)	Substances intended for use in the diagnosis, care, mitigation, treatment, or				
17			prevention of disease in man or animals;				
18		(c)	Substances (other than food) intended to affect the structure or any function of				
19			the body of man or animals; and				
20		(d)	Substances intended for use as a component of any article specified in this				
21			subsection.				

It does not include devices or their components, parts, or accessories;

23

24

25

26

27

(14) "Good faith prior examination," as used in KRS Chapter 218A and for criminal prosecution only, means an in-person medical examination of the patient conducted by the prescribing practitioner or other health-care professional routinely relied upon in the ordinary course of his or her practice, at which time the patient is physically examined and a medical history of the patient is obtained. "In-person"

Page 12 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

1		inclu	des telehealth examinations. This subsection shall not be applicable to hospice
2		provi	iders licensed pursuant to KRS Chapter 216B;
3	(15)	"Haz	ardous chemical substance" includes any chemical substance used or intended
4		for us	se in the illegal manufacture of a controlled substance as defined in this section
5		or th	ne illegal manufacture of methamphetamine as defined in KRS 218A.1431,
6		which	h:
7		(a)	Poses an explosion hazard;
8		(b)	Poses a fire hazard; or
9		(c)	Is poisonous or injurious if handled, swallowed, or inhaled;
10	(16)	"Hero	oin" means a substance containing any quantity of heroin, or any of its salts,
11		isomo	ers, or salts of isomers;
12	(17)	"Hyd	rocodone combination product" means a drug with:
13		(a)	Not more than three hundred (300) milligrams of dihydrocodeinone, or any of
14			its salts, per one hundred (100) milliliters or not more than fifteen (15)
15			milligrams per dosage unit, with a fourfold or greater quantity of an
16			isoquinoline alkaloid of opium; or
17		(b)	Not more than three hundred (300) milligrams of dihydrocodeinone, or any of
18			its salts, per one hundred (100) milliliters or not more than fifteen (15)
19			milligrams per dosage unit, with one (1) or more active, nonnarcotic
20			ingredients in recognized therapeutic amounts;
21	(18)	"Imn	nediate precursor" means a substance which is the principal compound
22		comn	monly used or produced primarily for use, and which is an immediate chemical
23		interr	mediary used or likely to be used in the manufacture of a controlled substance
24		or me	ethamphetamine, the control of which is necessary to prevent, curtail, or limit
25		manu	ufacture;
26	<u>(19)</u>	''Ind	ustrial hemp" has the same meaning as in Section 1 of this Act;
27	(20)	''Ind	ustrial hemp products" has the same meaning as in Section 1 of this Act;

Page 13 of 25 SB021840.100 - 1324 - XXXX Senate Committee Substitute

1	(21) [(19]) "Intent to manufacture" means any evidence which demonstrates a person's
2	conscious objective to manufacture a controlled substance or methamphetamine.
3	Such evidence includes but is not limited to statements and a chemical substance's
4	usage, quantity, manner of storage, or proximity to other chemical substances or
5	equipment used to manufacture a controlled substance or methamphetamine;
6	(22)[(20)] "Isomer" means the optical isomer, except as used in KRS 218A.050(3) and
7	218A.070(1)(d). As used in KRS 218A.050(3), the term "isomer" means the optical,
8	positional, or geometric isomer. As used in KRS 218A.070(1)(d), the term "isomer"
9	means the optical or geometric isomer;
10	(23)[(21)] "Manufacture," except as provided in KRS 218A.1431, means the production,
11	preparation, propagation, compounding, conversion, or processing of a controlled
12	substance, either directly or indirectly by extraction from substances of natural
13	origin or independently by means of chemical synthesis, or by a combination of
14	extraction and chemical synthesis, and includes any packaging or repackaging of the
15	substance or labeling or relabeling of its container except that this term does not
16	include activities:
17	(a) By a practitioner as an incident to his or her administering or dispensing of a
18	controlled substance in the course of his or her professional practice;
19	(b) By a practitioner, or by his or her authorized agent under his supervision, for
20	the purpose of, or as an incident to, research, teaching, or chemical analysis
21	and not for sale; or
22	(c) By a pharmacist as an incident to his or her dispensing of a controlled
23	substance in the course of his or her professional practice;
24	(24)[(22)] "Marijuana" means all parts of the plant Cannabis sp., whether growing or
25	not; the seeds thereof; the resin extracted from any part of the plant; and every
26	compound, manufacture, salt, derivative, mixture, or preparation of the plant, its
27	seeds or resin or any compound, mixture, or preparation which contains any

Page 14 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

1	quantity of these substances. The term "marijuana" does not include:
2	(a) Industrial hemp that is in the possession, custody, or control of a person who
3	holds a license issued by the Department of Agriculture permitting that
4	person to cultivate, handle, or process industrial hemp; or [as defined in
5	KRS 260.850;]
6	(b) Industrial hemp products that do not include any living plants, viable seeds,
7	<u>leaf materials, or floral materials;</u>
8	(c)[(b)] The substance cannabidiol, when transferred, dispensed, or administered
9	pursuant to the written order of a physician practicing at a hospital or
10	associated clinic affiliated with a Kentucky public university having a college
11	or school of medicine; or
12	$\underline{(d)}$ [(e)] For persons participating in a clinical trial or in an expanded access
13	program, a drug or substance approved for the use of those participants by the
14	United States Food and Drug Administration;
15	(25)[(23)] "Medical history," as used in KRS Chapter 218A and for criminal prosecution
16	only, means an accounting of a patient's medical background, including but not
17	limited to prior medical conditions, prescriptions, and family background;
18	(26)[(24)] "Medical order," as used in KRS Chapter 218A and for criminal prosecution
19	only, means a lawful order of a specifically identified practitioner for a specifically
20	identified patient for the patient's health-care needs. "Medical order" may or may
21	not include a prescription drug order;
22	(27)[(25)] "Medical record," as used in KRS Chapter 218A and for criminal prosecution
23	only, means a record, other than for financial or billing purposes, relating to a
24	patient, kept by a practitioner as a result of the practitioner-patient relationship;
25	(28)[(26)] "Methamphetamine" means any substance that contains any quantity of
26	methamphetamine, or any of its salts, isomers, or salts of isomers;
27	(29) [(27)] "Narcotic drug" means any of the following, whether produced directly or

Page 15 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

1	indi	indirectly by extraction from substances of vegetable origin, or independently by		
2	mea	means of chemical synthesis, or by a combination of extraction and chemical		
3	synt	hesis:		
4	(a)	Opium and opiate, and any salt, compound, derivative, or preparation of		
5		opium or opiate;		
6	(b)	Any salt, compound, isomer, derivative, or preparation thereof which is		
7		chemically equivalent or identical with any of the substances referred to in		
8		paragraph (a) of this subsection, but not including the isoquinoline alkaloids		
9		of opium;		
10	(c)	Opium poppy and poppy straw;		
11	(d)	Coca leaves, except coca leaves and extracts of coca leaves from which		
12		cocaine, ecgonine, and derivatives of ecgonine or their salts have been		
13		removed;		
14	(e)	Cocaine, its salts, optical and geometric isomers, and salts of isomers;		
15	(f)	Ecgonine, its derivatives, their salts, isomers, and salts of isomers; and		
16	(g)	Any compound, mixture, or preparation which contains any quantity of any of		
17		the substances referred to in paragraphs (a) to (f) of this subsection;		
18	<u>(30)</u> [(28)]	"Opiate" means any substance having an addiction-forming or addiction-		
19	susta	aining liability similar to morphine or being capable of conversion into a drug		
20	havi	ng addiction-forming or addiction-sustaining liability. It does not include,		
21	unle	ss specifically designated as controlled under KRS 218A.030, the		
22	dext	rorotatory isomer of 3-methoxy-n-methylmorphinan and its salts		
23	(dex	tromethorphan). It does include its racemic and levorotatory forms;		
24	<u>(31)</u> [(29)]	"Opium poppy" means the plant of the species papaver somniferum L., except		
25	its s	eeds;		
26	<u>(32)[(30)]</u>	"Person" means individual, corporation, government or governmental		

Page 16 of 25 SB021840.100 - 1324 - XXXX Senate Committee Substitute

27

subdivision or agency, business trust, estate, trust, partnership or association, or any

1	other legal entity;
2	(33)[(31)] "Physical injury" has the same meaning it has in KRS 500.080;
3	(34)[(32)] "Poppy straw" means all parts, except the seeds, of the opium poppy, after
4	mowing;
5	(35)[(33)] "Pharmacist" means a natural person licensed by this state to engage in the
6	practice of the profession of pharmacy;
7	(36)[(34)] "Practitioner" means a physician, dentist, podiatrist, veterinarian, scientific
8	investigator, optometrist as authorized in KRS 320.240, advanced practice
9	registered nurse as authorized under KRS 314.011, or other person licensed
10	registered, or otherwise permitted by state or federal law to acquire, distribute
11	dispense, conduct research with respect to, or to administer a controlled substance
12	in the course of professional practice or research in this state. "Practitioner" also
13	includes a physician, dentist, podiatrist, veterinarian, or advanced practice registered
14	nurse authorized under KRS 314.011 who is a resident of and actively practicing in
15	a state other than Kentucky and who is licensed and has prescriptive authority for
16	controlled substances under the professional licensing laws of another state, unless
17	the person's Kentucky license has been revoked, suspended, restricted, or probated
18	in which case the terms of the Kentucky license shall prevail;
19	(37)[(35)] "Practitioner-patient relationship," as used in KRS Chapter 218A and for
20	criminal prosecution only, means a medical relationship that exists between a
21	patient and a practitioner or the practitioner's designee, after the practitioner or his
22	or her designee has conducted at least one (1) good faith prior examination;
23	(38)[(36)] "Prescription" means a written, electronic, or oral order for a drug or
24	medicine, or combination or mixture of drugs or medicines, or proprietary
25	preparation, signed or given or authorized by a medical, dental, chiropody
26	veterinarian, optometric practitioner, or advanced practice registered nurse, and
27	intended for use in the diagnosis, cure, mitigation, treatment, or prevention of

Page 17 of 25 SB021840.100 - 1324 - XXXX Senate Committee Substitute

1	disease in man or other animals;
2	(39)[(37)] "Prescription blank," with reference to a controlled substance, means a
3	document that meets the requirements of KRS 218A.204 and 217.216;
4	(40)[(38)] "Presumptive probation" means a sentence of probation not to exceed the
5	maximum term specified for the offense, subject to conditions otherwise authorized
6	by law, that is presumed to be the appropriate sentence for certain offenses
7	designated in this chapter, notwithstanding contrary provisions of KRS Chapter
8	533. That presumption shall only be overcome by a finding on the record by the
9	sentencing court of substantial and compelling reasons why the defendant cannot be
10	safely and effectively supervised in the community, is not amenable to community-
11	based treatment, or poses a significant risk to public safety;
12	(41)[(39)] "Production" includes the manufacture, planting, cultivation, growing, or
13	harvesting of a controlled substance;
14	(42)[(40)] "Recovery program" means an evidence-based, nonclinical service that assists
15	individuals and families working toward sustained recovery from substance use and
16	other criminal risk factors. This can be done through an array of support programs
17	and services that are delivered through residential and nonresidential means;
18	(43)[(41)] "Salvia" means Salvia divinorum or Salvinorin A and includes all parts of the
19	plant presently classified botanically as Salvia divinorum, whether growing or not
20	the seeds thereof, any extract from any part of that plant, and every compound,
21	manufacture, derivative, mixture, or preparation of that plant, its seeds, or its
22	extracts, including salts, isomers, and salts of isomers whenever the existence of
23	such salts, isomers, and salts of isomers is possible within the specific chemical
24	designation of that plant, its seeds, or extracts. The term shall not include any other
25	species in the genus salvia;
26	(44)[(42)] "Second or subsequent offense" means that for the purposes of this chapter an
27	offense is considered as a second or subsequent offense, if, prior to his or her

Page 18 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

1	conv	viction of the offense, the offender has at any time been convicted under this
2	chap	ter, or under any statute of the United States, or of any state relating to
3	subs	tances classified as controlled substances or counterfeit substances, except that
4	a pr	for conviction for a nontrafficking offense shall be treated as a prior offense
5	only	when the subsequent offense is a nontrafficking offense. For the purposes of
6	this	section, a conviction voided under KRS 218A.275 or 218A.276 shall not
7	cons	titute a conviction under this chapter;
8	<u>(45)</u> [(43)]	"Sell" means to dispose of a controlled substance to another person for
9	cons	ideration or in furtherance of commercial distribution;
10	<u>(46)</u> [(44)]	"Serious physical injury" has the same meaning it has in KRS 500.080;
11	<u>(47)</u> [(45)]	"Synthetic cannabinoids or piperazines" means any chemical compound which
12	is no	at approved by the United States Food and Drug Administration or, if approved,
13	whic	ch is not dispensed or possessed in accordance with state and federal law, that
14	cont	ains Benzylpiperazine (BZP); Trifluoromethylphenylpiperazine (TFMPP); 1,1-
15	Dim	ethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-
16	napł	nthoyl)indole; 1-Pentyl-3-(1-naphthoyl)indole; dexanabinol (HU-211); or any
17	com	pound in the following structural classes:
18	(a)	Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole
19		structure with substitution at the nitrogen atom of the indole ring by an alkyl,
20		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
21		piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further
22		substituted in the indole ring to any extent and whether or not substituted in
23		the naphthyl ring to any extent. Examples of this structural class include but
24		are not limited to JWH-015, JWH-018, JWH-019, JWH-073, JWH-081,
25		JWH-122, JWH-200, and AM-2201;
26	(b)	Phenylacetylindoles: Any compound containing a 3-phenylacetylindole

Page 19 of 25 SB021840.100 - 1324 - XXXX Senate Committee Substitute

structure with substitution at the nitrogen atom of the indole ring by an alkyl,

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2haloalkyl, alkenyl, piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of this structural class include but are not limited to JWH-167, JWH-250, JWH-251, and RCS-8;

- Benzoylindoles: Any compound containing a 3-(benzoyl)indole structure with (c) substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of this structural class include but are not limited to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4;
- Cyclohexylphenols: Any compound containing 2-(3hydroxycyclohexyl)phenol structure with substitution at the 5-position of the an alkyl, haloalkyl. phenolic ring bv alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural class include but are not limited to CP 47,497 and its C8 homologue (cannabicyclohexanol);
- Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-(e) naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(Nmethyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include but are not limited to JWH-175, JWH-184, and JWH-185;
- (f) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole

Page 20 of 25 SB021840.100 - 1324 - XXXX Senate Committee Substitute

> structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include but are not limited to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

- Naphthylmethylindenes: compound Any containing a 1-(1-(g) naphthylmethyl)indene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include but are not limited to JWH-176;
- (h) Tetramethylcyclopropanoylindoles: Any compound containing a 3-(1tetramethylcyclopropoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not further substituted in the tetramethylcyclopropyl ring to any extent. Examples of this structural class include but are not limited to UR-144 and XLR-11;
- (i) Adamantoylindoles: Any compound containing a 3-(1-adamantoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cycloalkylmethyl, cycloalkylethyl, alkenyl, 1-(N-methyl-2piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring system to any extent. Examples of this structural class

Page 21 of 25 SB021840 100 - 1324 - XXXX Senate Committee Substitute

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

1		include but are not limited to AB-001 and AM-1248; or
2	(j)	Any other synthetic cannabinoid or piperazine which is not approved by the
3		United States Food and Drug Administration or, if approved, which is not
4		dispensed or possessed in accordance with state and federal law;
5	<u>(48)</u> [(46)]	"Synthetic cathinones" means any chemical compound which is not approved
6	by tl	ne United States Food and Drug Administration or, if approved, which is not
7	disp	ensed or possessed in accordance with state and federal law (not including
8	bupr	opion or compounds listed under a different schedule) structurally derived from
9	2-an	ninopropan-1-one by substitution at the 1-position with either phenyl, naphthyl
10	or th	iophene ring systems, whether or not the compound is further modified in one
11	(1) c	or more of the following ways:
12	(a)	By substitution in the ring system to any extent with alkyl, alkylenedioxy
13		alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further
14		substituted in the ring system by one (1) or more other univalent substituents
15		Examples of this class include but are not limited to 3,4
16		Methylenedioxycathinone (bk-MDA);
17	(b)	By substitution at the 3-position with an acyclic alkyl substituent. Examples of
18		this class include but are not limited to 2-methylamino-1-phenylbutan-1-one
19		(buphedrone);
20	(c)	By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
21		methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a
22		cyclic structure. Examples of this class include but are not limited to
23		Dimethylcathinone, Ethcathinone, and α -Pyrrolidinopropiophenone (α -PPP)
24		or
25	(d)	Any other synthetic cathinone which is not approved by the United States
26		Food and Drug Administration or, if approved, is not dispensed or possessed
27		in accordance with state or federal law;

Page 22 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

1	<u>(49)[(47)]</u>	"Synthetic drugs" means any synthetic cannabinoids or piperazines or any
2	synthe	etic cathinones;
3	<u>(50)</u> [(48)]	"Telehealth" has the same meaning it has in KRS 311.550;
4	<u>(51)</u> [(49)]	"Tetrahydrocannabinols" means synthetic equivalents of the substances
5	contai	ned in the plant, or in the resinous extractives of the plant Cannabis, sp. or
6	synthe	etic substances, derivatives, and their isomers with similar chemical structure
7	and pl	harmacological activity such as the following:
8	(a)	Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers;
9	(b)	Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers; and
10	(c)	Delta 3, 4 cis or trans tetrahydrocannabinol, and its optical isomers;
11	<u>(52)</u> [(50)]	"Traffic," except as provided in KRS 218A.1431, means to manufacture,
12	distrib	bute, dispense, sell, transfer, or possess with intent to manufacture, distribute,
13	disper	nse, or sell a controlled substance;
14	<u>(53)</u> [(51)]	"Transfer" means to dispose of a controlled substance to another person
15	witho	ut consideration and not in furtherance of commercial distribution; and
16	<u>(54)</u> [(52)]	"Ultimate user" means a person who lawfully possesses a controlled substance
17	for hi	s or her own use or for the use of a member of his or her household or for
18	admin	nistering to an animal owned by him or her or by a member of his or her
19	house	hold.
20	→Sec	etion 13. The following KRS sections are repealed:
21	260.8505	Purpose of KRS 260.850 to 260.869 declared to be the support of industrial
22	hemp	production, development, and commercialization Accomplishment of
23	purpo	se achieved through auspices of Industrial Hemp Commission, research, and
24	pursui	it of federal permits or waivers General Assembly finds that development of
25	indust	trial hemp is proper governmental purpose and important to Commonwealth's
26	well-b	peing.

Page 23 of 25
SB021840.100 - 1324 - XXXX Senate Committee Substitute

260.851 Administrative regulations to license research on industrial hemp and hemp

1	products and establish testing criteria and protocols.
2	260.853 Promotion of research and development of markets for Kentucky industrial
3	hemp and hemp products Responsibilities of the commission Establishment of
4	five year research program Demonstration plots overseen by University of
5	Kentucky Agricultural Experiment Station Research into new energy technologies
6	Coordination with universities and the Cabinet for Economic Development
7	Exemption from criminal liability Annual report.
8	260.854 Conditions and procedures for issuing industrial hemp research program grower
9	license and industrial hemp grower licenses Content and processing of
10	applications for licenses Criminal background checks Commissioner's
11	discretion in approving licenses License fees set by administrative regulations
12	Monitoring requirements.
13	260.855 Rights and duties of industrial hemp grower licensee Operational procedures
14	for licensed growers Standards for transporting industrial hemp off premises of
15	licensed grower Seizure and disposal of hemp deemed contraband.
16	260.856 Forfeiture of right to grow hemp following revocation of industrial hemp
17	grower license Failure to comply with administrative regulations Plea to or
18	conviction of felony Administrative hearings and appeals.
19	260.857 Kentucky Industrial Hemp Commission Membership.
20	260.859 Quorum for commission Chair and vice chair.
21	260.861 Meetings Compensation of members Staff services by Department of
22	Agriculture and University of Kentucky Agricultural Experiment Station.
23	260.863 Recommendations and annual report of commission.
24	260.865 Mandatory adoption of federal rules and regulations regarding industrial hemp-
25	- KRS 260.850 to 260.869 not to conflict with federal law.

Page 24 of 25 SB021840.100 - 1324 - XXXX Senate Committee Substitute

growth since the research pilot program's inception in 2014, an emergency is declared to

Whereas industrial hemp production has experienced dramatic

→ Section 14.

26

1 exist, and this Act takes effect upon its passage and approval by the Governor or upon its

2 otherwise becoming a law.

SB021840.100 - 1324 - XXXX Senate Committee Substitute